Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration

PMID: 36626622
Title: Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration
Authors: Díaz-González Á, Hernández-Guerra M, Pérez-Medrano I, Sapena V, Riveiro-Barciela M, Barreira-Díaz A, Gómez E, Morillas RM, Del Barrio M, Escudé L, Mateos B, Horta D, Gómez J, Conde I, Ferre-Aracil C, El Hajra I, Arencibía A, Zamora J, Fernández A, Salcedo M, Molina E, Soria A, Estévez P, López C, Álvarez-Navascúes C, García-Retortillo M, Crespo J, Londoño MC; ColHai Registry.
Citation: Hepatology. 2023 Apr 1;77(4):1095-1105. doi: 10.1097/HEP.0000000000000018. Epub 2023 Jan 3.
First Author: Díaz-González Á
Journal/Book: Hepatology
Publication Year: 2023
Create Date: 2023/01/10
PMCID:
NIHMS ID:
DOI: 10.1097/HEP.0000000000000018